{"entity":{"id":"nct03428477","kind":"trial","name":"EPA for Metastasis Trial 2","aka":["EMT2"],"tldr":"A phase 3 trial in colorectal cancer, run by Mark A Hull, PhD FRCP, active but no longer recruiting.","summary":"EPA for Metastasis Trial 2 is a phase 3, randomised interventional study registered as NCT03428477 by Mark A Hull, PhD FRCP, with a registry enrolment figure of 418 participants, started 2018-05-02 and due to reach its primary completion in 2025-11-30. Interventions recorded: Icosapent Ethyl; Placebo. Conditions listed: Liver Metastasis; Colon Cancer. Primary outcome: Progression Free Survival (PFS). Colorectal eligibility wording from the registry: \"* Histological diagnosis of colorectal cancer with evidence of liver metastases\". Sites: United Kingdom. United Kingdom sites listed: 13. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT03428477","url":"https://clinicaltrials.gov/study/NCT03428477"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["colon-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["UK sites (registry): Oxford University Hospital NHS Foundation Trust (Oxford); Hampshire Hospitals NHS Foundation Trust (Basingstoke); Aintree University Hospitals NHS Foundation Trust (Aintree); University Hospitals Birmingham NHS Foundation Trust (Birmingham); Cambridge UniversityHospitals NHS Foundation Trust (Cambridge); University Hospital of Wales (Cardiff); Leeds Teaching Hospitals NHS Foundation Trust (Leeds); King's College London (London); Royal Free London NHS Foundation Trust (London); Newcastle Upon Tyne Hospitals NHS Foundation Trust (Newcastle); Nottingham University Hospitals NHS Trust (Nottingham); Sheffield Teaching Hospitals NHS Foundation Trust (Sheffield) and 1 more."],"nct":"NCT03428477","phase":"3","setting":"A Randomised Placebo-controlled Phase III Trial of the Effect of the Omega-3 Fatty Acid Eicosapentaenoic Acid (EPA) on Colorectal Cancer Recurrence and Survival After Surgery for Resectable Liver Metastases","sponsor":"Mark A Hull, PhD FRCP","enrolled":418,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct03428477/","neighbours":{"cancer":[{"id":"colon-cancer","kind":"cancer","name":"Colon cancer (adenocarcinoma of the colon)","route":"/cancers/colon-cancer/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}